Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of anlotinib with PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma: A real-world study.
Authors
Kehe Chen
The People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China;
Kehe Chen , Xianshi Huang , Lei Yu , Jianxun Lu , Fei Huang , Zhiguang Wang , Yan Wei , Encun Hou , Min Luo , Shiqing Huang , Hongbo Hu , Mei Ou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04954521
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 583)
DOI
10.1200/JCO.2023.41.4_suppl.583
Abstract #
583
Poster Bd #
E15
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of anlotinib with or without PD-1 blockades in the treatment of advanced primary hepatocellular carcinoma (HCC): A real-world exploratory study.
First Author: Xiao-Qi Chen
Poster
2023 ASCO Annual Meeting
Efficacy and safety of PD-1/PD-L1 inhibitor plus platinum-based chemotherapy vs. platinum-based chemotherapy alone in patients with previously untreated advanced large-cell neuroendocrine cancer of the lung.
First Author: Fengchun Mu
Poster
2023 ASCO Annual Meeting
Efficacy and safety of IBI110 in combination with sintilimab and lenvatinib in first-line of advanced hepatocellular carcinoma: Preliminary results from a phase Ib study.
First Author: Ming Liu
Poster
2022 ASCO Annual Meeting
Cisplatin (Cis) combined with sintilimab (Sint) and niraparib (Nir) in advanced solid tumors: Updated results.
First Author: TAO Haitao